Core Insights - Perma-Pipe International Holdings, Inc. reported a net sales increase of 27.7% for Q2 2025, reaching $47.9 million compared to $37.5 million in the same quarter last year [1] - The growth in sales was attributed to higher sales volumes in both the Middle East and North America [1] - Gross profit for the quarter was $14.4 million, reflecting an increase of $0.9 million from $13.5 million in the prior year [1]

Core Viewpoint - Star Equity Fund's advocacy led to Servotronics agreeing to be acquired by TransDigm at a significant premium, creating substantial value for shareholders [1][2]. Group 1: Transaction Details - TransDigm will acquire all outstanding shares of Servotronics at $47.00 per share in an all-cash transaction, representing a 357% premium over the closing price on May 16, 2025 [1]. - The transaction was a result of a strategic review initiated by Servotronics' Board, influenced by Star Equity Fund's sustained pressure and advocacy [2]. Group 2: Shareholder Advocacy - Star Equity Fund's campaign included director nominations and various communications with the Board, which led to shareholder-friendly actions that may not have occurred otherwise [2]. - The advocacy highlighted that Servotronics' shares were undervalued and that its intrinsic value was higher than its trading price as a standalone public company [2]. Group 3: Stakeholder Benefits - The acquisition by TransDigm is expected to benefit all stakeholders of Servotronics, including employees and customers, according to the Portfolio Manager of Star Equity Fund [3]. - The efforts of significant shareholders and directors contributed to achieving this favorable outcome for all shareholders, including the Company's Employee Stock Ownership Plan (ESOP) [3]. Group 4: Company Background - Star Equity Fund, LP is focused on unlocking shareholder value through engagement with management teams across its portfolio companies [4]. - Star Equity Holdings, Inc. operates in three business divisions: Building Solutions, Energy Services, and Investments [5].

Core Viewpoint - Mural Oncology has decided to discontinue all clinical development of nemvaleukin alfa following unsatisfactory results from the ARTISTRY-6 and ARTISTRY-7 trials, and will explore strategic alternatives to maximize shareholder value [1][2][3] Company Developments - Mural Oncology will reduce its workforce by approximately 90% as part of its restructuring efforts [1] - The company had approximately $144.4 million in cash, cash equivalents, and marketable securities as of December 31, 2024 [1] - Mural has engaged Lucid Capital Markets, LLC as its financial advisor to assist in exploring strategic alternatives [1][3] Clinical Trial Results - The ARTISTRY-6 trial did not achieve its primary endpoint in evaluating nemvaleukin as a monotherapy for mucosal melanoma [2] - Preliminary data from ARTISTRY-6 cohort 3, which assessed less-frequent intravenous dosing in cutaneous melanoma patients, also did not show sufficient activity to warrant continuation [2] - Interim overall survival results from the ARTISTRY-7 trial in platinum-resistant ovarian cancer contributed to the decision to halt development of nemvaleukin [2] Strategic Alternatives - Mural is considering various strategic alternatives, including potential offers for acquisition, mergers, or other business combinations [3] - The company is currently in an "offer period" as defined by the Irish Takeover Rules, which may affect the exploration of strategic alternatives [5][6] Regulatory Considerations - Mural is subject to the Irish Takeover Panel Act and must comply with specific disclosure requirements during the strategic evaluation process [5][10]